Novartis AG ADR (NVS)vsNexalin Technology Inc. (NXL)
NVS
Novartis AG ADR
$150.88
+0.72%
HEALTHCARE · Cap: $291.32B
NXL
Nexalin Technology Inc.
$0.34
-2.86%
HEALTHCARE · Cap: $7.49M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 20572147% more annual revenue ($56.69B vs $275,580). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
NXL
Avoid18
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-63.9%
Fair Value
$92.92
Current Price
$150.88
$57.96 premium
Intrinsic value data unavailable for NXL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Reasonable price relative to book value
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -319.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : NXL
The strongest argument for NXL centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : NXL
The primary concerns for NXL are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NXL carries more volatility with a beta of 4.04 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 18/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Nexalin Technology Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Nexalin Technology Inc. is a pioneering medical technology firm dedicated to transforming the treatment of neurological and psychiatric disorders through its proprietary transcranial electrical stimulation devices. By offering non-invasive solutions for prevalent mental health issues such as anxiety, depression, and substance addiction, the company underscores its commitment to improving patient outcomes and advancing accessible mental health care. With a robust research background and a strategic focus on tapping into the rising demand for innovative healthcare solutions, Nexalin is well-positioned for growth in the rapidly expanding digital health sector, presenting a compelling investment opportunity for institutional investors.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?